APH

ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCQB: APCSF) ("ALDA") has been notified that the Canadian Intellectual Property Office ("CIPO") has accepted ALDA's patent application that describes the composition, production methods and certain therapeutic uses for ALDA's T36® formulation.

In addition, the Company has two patents issued in the both the US and Australia, one issued in China and one pending in both China and the EU. An additional patent application, seeking protection for the T36® formula in combination with anesthetics, analgesics and anti-inflammatories for the treatment of a wide range of topical infections has been filed in the US and the EU.

Dr. Terrance Owen, President & CEO, states, "Notification that the patent will now be issued in Canada provides further evidence that our intellectual property is very robust. We are gratified to see rapid allowance of the patent applications in a number of jurisdictions. Clearly, ALDA's T36® formulation is unique and is a significant asset to the company."

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: ALDA Pharmaceuticals Corp. Scott Young Investor Relations 604-377-5781 or 604-521-8300 Ext 203 604-521-8322 (FAX) scott_young@aldacorp.com www.aldacorp.com